BCAL Diagnostics (ASX:BDX) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. BCAL Diagnostics's annualized Gross Profit for the quarter that ended in Dec. 2023 was A$0.00 Mil. BCAL Diagnostics's average Total Assets over the quarter that ended in Dec. 2023 was A$8.40 Mil. Therefore, BCAL Diagnostics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.

BCAL Diagnostics Gross-Profit-to-Asset % Historical Data

The historical data trend for BCAL Diagnostics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Gross-Profit-to-Asset % Chart

BCAL Diagnostics Annual Data

Trend

Jun22

Jun23

Gross-Profit-to-Asset %

BCAL Diagnostics Semi-Annual Data
	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of BCAL Diagnostics's Gross-Profit-to-Asset %

For the Diagnostics & Research subindustry, BCAL Diagnostics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BCAL Diagnostics's Gross-Profit-to-Asset % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's Gross-Profit-to-Asset % falls into.

BCAL Diagnostics Gross-Profit-to-Asset % Calculation

BCAL Diagnostics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Jun. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Jun. 2023 )	/	( (Total Assets (A: Jun. 2022 )	+	Total Assets (A: Jun. 2023 ))	/ count )
	=	0	/	( (10.59	+	8.371)	/ 2 )
	=	0	/	9.4805
	=	0.00 %

BCAL Diagnostics's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (8.371	+	8.422)	/ 2 )
	=	0	/	8.3965
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

BCAL Diagnostics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230

Website

https://www.bcaldiagnostics.com

BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.